Literature DB >> 29727311

Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.

Steve Walston1, Joseph Salloum, Carmine Grieco, Evan Wuthrick, Dayssy A Diaz, Christian Barney, Andrei Manilchuk, Carl Schmidt, Mary Dillhoff, Timothy M Pawlik, Terence M Williams.   

Abstract

OBJECTIVES: The role of radiation therapy (RT) in resected pancreatic cancer (PC) remains incompletely defined. We sought to determine clinical variables which predict for local-regional recurrence (LRR) to help select patients for adjuvant RT.
MATERIALS AND METHODS: We identified 73 patients with PC who underwent resection and adjuvant gemcitabine-based chemotherapy alone. We performed detailed radiologic analysis of first patterns of failure. LRR was defined as recurrence of PC within standard postoperative radiation volumes. Univariate analyses (UVA) were conducted using the Kaplan-Meier method and multivariate analyses (MVA) utilized the Cox proportional hazard ratio model. Factors significant on UVA were used for MVA.
RESULTS: At median follow-up of 20 months, rates of local-regional recurrence only (LRRO) were 24.7%, LRR as a component of any failure 68.5%, metastatic recurrence (MR) as a component of any failure 65.8%, and overall disease recurrence (OR) 90.5%. On UVA, elevated postoperative CA 19-9 (>90 U/mL), pathologic lymph node positive (pLN+) disease, and higher tumor grade were associated with increased LRR, MR, and OR. On MVA, elevated postoperative CA 19-9 and pLN+ were associated with increased MR and OR. In addition, positive resection margin was associated with increased LRRO on both UVA and MVA.
CONCLUSIONS: About 25% of patients with PC treated without adjuvant RT develop LRRO as initial failure. The only independent predictor of LRRO was positive margin, while elevated postoperative CA 19-9 and pLN+ were associated with predicting MR and overall survival. These data may help determine which patients benefit from intensification of local therapy with radiation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29727311      PMCID: PMC6215749          DOI: 10.1097/COC.0000000000000452

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  34 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings.

Authors:  Shoichi Hishinuma; Yoshiro Ogata; Moriaki Tomikawa; Iwao Ozawa; Kaoru Hirabayashi; Seiji Igarashi
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

3.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

4.  Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.

Authors:  Arsen Osipov; Nicholas Nissen; Joanne Rutgers; Deepti Dhall; Jason Naziri; Shefali Chopra; Quanlin Li; Andrew Eugene Hendifar; Richard Tuli
Journal:  Ann Surg Oncol       Date:  2017-09-05       Impact factor: 5.344

5.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

6.  Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.

Authors:  Charles E Rutter; Henry S Park; Christopher D Corso; Nataniel H Lester-Coll; Brandon R Mancini; Debra N Yeboa; Kimberly L Johung
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

7.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

Review 8.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

Authors:  M J Duffy; C Sturgeon; R Lamerz; C Haglund; V L Holubec; R Klapdor; A Nicolini; O Topolcan; V Heinemann
Journal:  Ann Oncol       Date:  2009-08-18       Impact factor: 32.976

9.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

10.  Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma.

Authors:  Jennifer L Gnerlich; Samuel R Luka; Anjali D Deshpande; Bernard J Dubray; Joshua S Weir; Danielle H Carpenter; Elizabeth M Brunt; Steven M Strasberg; William G Hawkins; David C Linehan
Journal:  Arch Surg       Date:  2012-08
View more
  4 in total

1.  Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy.

Authors:  Caitlin A McIntyre; Constantinos P Zambirinis; Alessandra Pulvirenti; Joanne F Chou; Mithat Gonen; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Murray F Brennan; Jeffrey A Drebin; William R Jarnagin; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2020-05-25       Impact factor: 5.344

2.  Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance.

Authors:  V O Oria; P Bronsert; A R Thomsen; M C Föll; C Zamboglou; Luciana Hannibal; S Behringer; M L Biniossek; C Schreiber; A L Grosu; L Bolm; D Rades; T Keck; M Werner; U F Wellner; O Schilling
Journal:  Transl Oncol       Date:  2018-08-30       Impact factor: 4.243

3.  A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection.

Authors:  Adam R Wolfe; Patrick Wald; Amy Webb; Nikhil Sebastian; Steve Walston; Ryan Robb; Wei Chen; Marall Vedaie; Mary Dillhoff; Wendy L Frankel; Wooil Kwon; Jin-Young Jang; Terence M Williams
Journal:  Oncotarget       Date:  2020-03-10

4.  Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer.

Authors:  John R Bergquist; Cornelius A Thiels; Christopher R Shubert; Tommy Ivanics; Elizabeth B Habermann; Santhi S Vege; Travis E Grotz; Sean P Cleary; Rory L Smoot; Michael L Kendrick; David M Nagorney; Mark J Truty
Journal:  Cancer Med       Date:  2021-07-21       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.